Select Your Region

We noticed you visit this page from United States. Please select your preferred region to continue

skip to content

Country Selector

Based on your location

Europe

North America

Latin America

Asia-Pacific

Healthcare Professional Verification

This section contains medical information for licensed healthcare professionals only. Please confirm your professional status to continue.

Newborn Hemoglobin disorders screening

The perfect match for screening hemoglobin disorders in newborns.

Published date: 3/8/2021 | Modified date: 6/9/2026

How do we diagnose Newborn Hemoglobin disorders?

Each day, more than 100,000 newborns worldwide are screened for metabolic, endocrine, and genetic disorders. While hemoglobin screening has a long-standing history in some countries, such as the USA, France and the UK, it has only recently been incorporated into newborn screening programs in others, including Portugal, Germany, and Australia.

The rising prevalence of hemoglobin disorders in regions where they were previously uncommon has increased awareness of the need for newborn screening.

Early detection has been shown to improve the lives of babies by enabling timely treatment and appropriate follow-up care.

The CAPI 3 NEONAT Hb kit is intended for the detection of normal hemoglobins (F and A) and abnormal hemoglobins (S, C, E, D and Bart’s) in blood from human newborn collected on filter paper. This qualitative analysis is performed by Capillary Electrophoresis with the CAPILLARYS 3 DBS automated instrument. The test result must be interpreted in conjunction with other biological and clinical findings.

Key benefits

The CAPILLARYS 3 DBS instrument, the latest, user-friendly, high-throughput solution for detecting hemoglobin variants and screening thalassemias in newborns.
  • Easy to Use

    Once the samples are punched and the plates are loaded, the instrument fully automates all steps, making it easy to operate and requiring minimal maintenance.

  • High Autonomy & Throughput

    Between one and eight full 96-well microplates can be processed in a single run, with a throughput of 74 tests per hour. Load-and-go workflow improves efficiency and reduces hands-on time.

  • Full traceability

    From sample punching with an automatic puncher to the export of results from the CE instrument software, patient information is automatically transferred via the sample's barcode, eliminating the risk of manual errors during ID entry.

  • High Resolution

    Thanks to the high-resolution hemoglobin separation provided by the Sebia CAPILLARYS 3 DBS device, the instrument produces a clear profile that facilitates the identification of abnormal hemoglobin variants (Hb S, C, D, E, etc.) as well as thalassemia-related abnormalities such as Hb H and Hb Bart’s.

  • Automatic Result Interpretation

    The software automatically classifies samples using a color-coding system to distinguish between normal or abnormal results, allowing laboratories to quickly identify pathological findings while quickly releasing non-pathological samples.

Main characteristics

Test principle

  • The NEONAT Hb assay is based on the principle of Capillary Electrophoresis in free solution. Hemoglobin fractions are separated in silica capillaries, by their electrophoretic mobility and electroosmotic flow at a high voltage in an alkaline buffer.
  • The diluent is formulated to counteract the hemoglobin oxidation in the blood spot, that occurs during drying, room-temperature transportation, and extended storage prior to analysis.
  • Hemoglobin fractions are directly detected at the specific absorbance of 415 nm. The resulting pattern is divided into 13 zones to facilitate interpretation of normal hemoglobins (F and A) and abnormal hemoglobin (S, C, D, E and Bart’s).

Sample type

Dried neonatal blood spots are punched (standard size of 3.2 mm), eluted in distilled water, and directly analysed using the CAPILLARYS 3 DBS instrument.

Performances

                                         Throughput (tests/hour)*

CAPI 3 NEONAT Hb

CAPILLARYS 3 DBS               74

*Firmware-dependent; contact your local Sebia representative for current information.

Product details

Dedicated reagent kit, Hemolysing solution and Hb AF control.

Reagents

  • CAPI 3 NEONAT Hb – P/N: 2506
  • CAPI 3 NEONAT Hemolysing solution – P/N: 2563

Controls

  • CAPI 3 NEONAT Hb AF Control – P/N: 4757
  • Hb AFSC Control – P/N: 4792 (optional pathological control)

Consumables

  • CAPILLARYS 3 DBS Microplates – P/N: 2578 (10 units – 96 well barcoded microplates)

Knowledge & Science

No content available.

Newborn Hemoglobin disorders screening test can be performed on the following instrument

  • The high throughput solution for newborn hemoglobin disorders screening.

    CAPILLARYS 3 DBS

Test related to Newborn Hemoglobin disorders screening

This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.

Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.